Does an optimal asymmetric dimethylarginine level suggest less nitric oxide synthase inhibition?

ADMA is an endogenous regulator of nitric-oxide (NO) signaling, relevant to endothelial vasodilation. The claim is mechanistically sound, but a single circulating ADMA result has limited ability to establish an individual’s NO production or vascular function.

Mechanism

• ADMA inhibits nitric-oxide synthase (NOS), particularly endothelial NOS (eNOS), by competing with L-arginine at the active site. Purified-enzyme studies report an eNOS inhibition constant (Ki) of approximately 0.9 µM; excess L-arginine can reverse inhibition.
• By reducing NOS activity, higher ADMA can reduce NO production/bioavailability and thereby oppose endothelium-dependent vasodilation. The biological effect depends importantly on the ADMA:L-arginine balance, not ADMA alone.
• Kinetics are isoform- and context-dependent: nNOS has shown noncompetitive behavior in some experiments. At 100 µM L-arginine, appreciable eNOS inhibition in purified preparations required ADMA concentrations >10 µM, whereas typical healthy plasma ADMA is about 0.4–0.6 µM.

Human vascular evidence

• Higher circulating ADMA is independently associated with poorer brachial flow-mediated dilation (FMD), a measure of endothelium-dependent relaxation. This was observed in the Young Finns cohort (n=2,096) after adjustment for cardiovascular and renal factors, and in 111 low-risk healthy nonsmokers.
• Experimental ADMA elevation has impaired vascular function, supporting a biologically meaningful link beyond correlation.

Interpretation in practice

• A low or favorable ADMA result relative to the laboratory’s assay-specific reference interval is consistent with less NOS inhibition and with preserved endothelial relaxation.
• “Optimal” is not a validated universal clinical target. Reported healthy ranges vary substantially—approximately 0.34–1.10 µmol/L by HPLC and 0.25–0.92 µmol/L by ELISA—and ADMA alone does not directly measure endothelial function or NO synthesis.

Bottom line

• The claim is substantially supported: favorable ADMA is compatible with reduced restraint on NO signaling and better-preserved endothelial relaxation, but should be interpreted as contextual supportive evidence rather than proof of an individual’s vascular NO status.